Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 3 , Pages 240-248, March 2009

Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical Pearls

Drs. Daughton and Kratochvil are with the University of Nebraska Medical Center

Accepted 23 November 2008.

Disclosure: Dr. Kratochvil receives research funding from NIMH Grant 5K23MH06612701A1. He receives grant support from Eli Lilly, McNeil, Shire, Abbott, Somerset, and Cephalon; is a consultant for Eli Lilly, AstraZeneca, Abbott, and Pfizer. He is the editor of the Brown University Child & Adolescent Psychopharmacology Update, a member of the REACH Institute Primary Pediatric Psychopharmacology Steering Committee, a member of the American Professional Society for ADHD and Related Disorders Board of Directors, and on the CME Outfitters Professional Advisory Board. He receives study drugs for an NIMH-funded study from Eli Lilly. The other author reports no conflicts of interest.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials, and includes discussions that are “off-label” from the perspective of the U.S. Food and Drug Administration. Although we fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care, this column focuses primarily on psychopharmacological management. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

PII: S0890-8567(09)60023-X

doi:10.1097/CHI.0b013e318197748f

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 3 , Pages 240-248, March 2009

Article Tools

* Image Usage & Resolution